AstraZeneca shares fall after lung cancer treatment fails to meet expectations
Pharmaceutical giant AstraZeneca has seen its share price plunge significantly, down 5%, following the release of less favorable results from a major lung cancer drug clinical trial. This development has raised concerns among investors and stakeholders about the future prospects of the company's on...
